10x Genomics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. We are going to kick it off. I am Tycho Peterson from the Life Science team. Pleased to have 10x with us. Welcome, Serge. Welcome, Adam. Maybe just kick it off with a quick recap from 3Q, just thinking a little bit about some of the momentum here as we head into next year. Obviously, new product cycle. We have a number of things going on. Just, what were the positives and negatives out of the quarter and in 2027?
Yeah, no, probably the biggest positive and continuing story of this year has been the momentum on the Atera. We came into this year really enthused about the potential of the platform. It was really fun to tell the world about it back in April. Consistently since that point, it has been really fun to be out there and just see the customer enthusiasm, which has been translating into all manner of kinds of metrics in terms of order flow, in terms of funnel, just the resonance with customers out there. I think that continued to be. That was the big story of Q2. That continued to be, I would say, the big story of Q3.
Now, overlay on top of that, we always knew that once we announced the Atera, there is going to be some pressure on our business when it comes to existing spatial business and consumables. Coming into Q3, we expected that to be the biggest pinch point. What has been a really nice, also positive development is the continuing strength in the consumable in the existing business that we saw. A lot of the quarter played out roughly as we expected, as we communicated, but there definitely were some upsides that we saw in our numbers, specifically on the spatial consumables, but also just continuing enthusiasm for Atera.
Of course, we also saw really nice trends continuing along on our single-cell business, keep driving reaction volume, and just overall the big macro trends while there is the academic and government funding are still pressured. Overall, the macro environment has been trending, I would say, in our favor, supported by this continued interest in AI and also with our current slate of products and translational work.
How is the early user base evolved for Atera relative to your initial assumptions around high-throughput clinical spatial labs? Just talk a little bit about the evolution of the customer base.
Yeah. Just to be clear, it's very early, right? We literally told the world for the first time in April that this thing existed. No one expected it. No one could imagine that that set of capabilities was coming, was going to be available to the world. Our initial go-to-market strategy naturally was focused on customers that are already existing Xenium instrument owners, users. The idea being that those are the people that would be most ready to ramp, to take advantage of Atera, and to really spread the word and serve the rest of the ecosystem out of the gate.
Now, certainly those customers have been our focus, and there's a lot of interest from existing Xenium instrument owners, but also a very large fraction of the initial orders, and even more so for the funnel, is from people who are not currently owners of Xeniums. Some of them are actually new to spatial completely. So that's been really great to see. The breadth of interest, the breadth of applications, and the depth has been really, I would say, even in excess of our expectations. Our expectations were pretty high going into the launch.
I guess, obviously still early days, but just thinking about the breadth of customers and pull-through assumptions, maybe one for Adam, how do we think about the framework for pull-through, and when will we get more granularity there?
Yeah. Well, I hate to sound like a broken record, but it's really early. We've just got such a small N out there. Most of the customers so far from an order perspective are really interested in the whole transcriptome. We're really trying to prioritize instruments because we've got demand outstrips supply. We're trying to make sure they're getting instruments into the hands of folks that have got projects lined up, that are well-funded, ready to start pulling through consumables. We'll give more color on that when we get into Q1 and guidance.
You gave some numbers on the scalability for next year, which was helpful. I guess, are there rate-limiting factors we need to think about to scale beyond that that are important?
Yeah. I mean, what we've said, just to reiterate, was that we would sell 50 Ateras this year. One, just want to be clear, that doesn't mean we're at that point where we're building 50. It's an ambitious target, but it's a target we feel really confident in. As we get into Q1, feel confident we'll be able to build 50 a quarter. Maybe just as important, if not more important, is we're really optimizing for customer success. Ensuring that we've got field service engineer capacity and capability to get these things installed. As you can imagine, nothing out of the ordinary, but I mean, each one of the very small N thus far has had some little tweak, whether that's a site readiness issue, something else that may have happened in shipping.
Really trying to work out and iron out any of those kinks. Then having field application support on site just to make sure that the customer's up and running, successful, that they've got a consumables order that's ready to go, so that when we leave, through telemetry, we can actually see they're running, they're successfully running the instrument.
I guess in terms of expanding the user base beyond the Xenium customers, just talk about some of the leading indicators. I mean, obviously there's grant filings, but what else are you tracking as you think about expanding the market?
Yeah. So, first of all, the most direct measure is just like, okay, the customers are actually putting in the money and the people in the funnel. Like I said earlier, there's a greater than expected fraction of them that are new to Xenium instruments. So that's a really encouraging sign to begin with. Then you kind of look at all the different sort of applications, right, that are being used and coming online. So certainly AI is a big deal. We can talk a lot more about it, but in many ways, Atera is perfectly built for this new era of AI, and not by accident, right? That is kind of a core premise of the company, is to build tools that can measure biology, the right kind of biology at massive scale and high resolution.
Atera kind of perfectly fits this moment in a way that no previous spatial technology really did. We're seeing a lot of interest, kind of a very large scale, like different institutions, whether it's kind of big consortia or companies, biotech companies, AI kind of native companies that are gearing up to use this technology. Or, kind of made a reference on our earnings call to companies that are like diagnostics companies that are sitting on large numbers of clinical samples that are really valuable samples, that they now can apply this technology to extract maximum information content from and correlate it to clinical data as well. So, I've been actually finding just in my personal conversation with customers, I was just, one of the things you take advantage of when you come out to these conferences, you go and you see customers.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
